NASDAQ:LXEO - Nasdaq - US52886X1072 - Common Stock - Currency: USD
NASDAQ:LXEO (5/27/2025, 1:57:50 PM)
2.649
-0.17 (-6.06%)
The current stock price of LXEO is 2.649 USD. In the past month the price decreased by -23.37%. In the past year, price decreased by -81.76%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.07 | 327.86B | ||
AMGN | AMGEN INC | 13.41 | 149.74B | ||
GILD | GILEAD SCIENCES INC | 14.05 | 135.30B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.21B | ||
REGN | REGENERON PHARMACEUTICALS | 13.69 | 65.48B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.29B | ||
ARGX | ARGENX SE - ADR | 99.33 | 35.60B | ||
ONC | BEIGENE LTD-ADR | 6.07 | 25.67B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.80B | ||
NTRA | NATERA INC | N/A | 21.54B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.49B | ||
BIIB | BIOGEN INC | 8.17 | 18.95B |
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
LEXEO THERAPEUTICS INC
345 Park Avenue South, Floor 6
New York City NEW YORK US
Employees: 69
Phone: 12125479879
The current stock price of LXEO is 2.649 USD. The price decreased by -6.06% in the last trading session.
The exchange symbol of LEXEO THERAPEUTICS INC is LXEO and it is listed on the Nasdaq exchange.
LXEO stock is listed on the Nasdaq exchange.
13 analysts have analysed LXEO and the average price target is 21.57 USD. This implies a price increase of 714.11% is expected in the next year compared to the current price of 2.649. Check the LEXEO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LEXEO THERAPEUTICS INC (LXEO) has a market capitalization of 87.95M USD. This makes LXEO a Micro Cap stock.
LEXEO THERAPEUTICS INC (LXEO) currently has 69 employees.
LEXEO THERAPEUTICS INC (LXEO) has a support level at 2.62 and a resistance level at 3.26. Check the full technical report for a detailed analysis of LXEO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LXEO does not pay a dividend.
LEXEO THERAPEUTICS INC (LXEO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.3).
The outstanding short interest for LEXEO THERAPEUTICS INC (LXEO) is 10.33% of its float. Check the ownership tab for more information on the LXEO short interest.
ChartMill assigns a fundamental rating of 1 / 10 to LXEO. While LXEO seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months LXEO reported a non-GAAP Earnings per Share(EPS) of -3.3. The EPS decreased by -22.18% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -86.97% | ||
ROE | -124.05% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 86% to LXEO. The Buy consensus is the average rating of analysts ratings from 13 analysts.